🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Significance of HER2-Low in DCIS How might it impact on clinical practice in the foreseeable future? Knowledge that DCIS with low HER2 expression is associated with less aggressive features could inform less aggressive future therapeutic interventions clinical-breast-cancer.com/article/S1526-…

Optimising inter-patient image registration for image-based data mining in breast radiotherapy - Physics and Imaging in Radiation Oncology phiro.science/article/S2405-…

Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project - Cancer Treatment Reviews cancertreatmentreviews.com/article/S0305-…👇

Dose constraints in #radiotherapy #BreastCancer ⛔️ all OARs ☢️ different fractionation schedules 🩺 proposed DVCs correlated with clinical endpoints #RadOnc for a 50 days' free access 👇🏼 authors.elsevier.com/c/1j-vNcA0-Idri

📌 The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis. OncoAlert #OncoAlertAF 🔗proud to share our research article: sciencedirect.com/science/articl… Agnese Prisco Maria Carmen De Santis Fiorenza De Rose Nadia Pasinetti

The Full Program for #SABCS24 is out SABCS Look who’s around… #radonc #medonc #surgonc #BreastCancer #OncoAlert OncoAlert Università di Firenze Azienda Ospedaliero-Universitaria Careggi sabcs.org/FullProgram

Oligometastatic #breastcancer is less responsive to SBRT. Is it due to patient selection or the chosen outcome? Some insights in this review. thebreastonline.com/article/S0960-… #radonc Maria Carmen De Santis Serena Di Cosimo Maria Grazia Carnevale

It is a great pleasure to be the second author of this important publication in Lancet Oncology on preplanned interym analysis of Europa Trial. Thanks to all 128 patients enrolled at Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano!!!! The Lancet Oncology Istituto Tumori

Completely agreee!!!

Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review is out! JAMA Oncology A robust clinical and analytical validation of biomarkers to ensure clinical utility for RT optimization is still needed ☢️ #radonc #OncoAlert OncoAlert ESTRO pubmed.ncbi.nlm.nih.gov/39820307/

📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial Immune-modulating SBRT avoids irradiation of tumour-draining lymph nodes

📣 #ESMOBreast25: Gain exclusive insights into the latest advancements in breast cancer treatment and care. ⏰ Register by 17 April and save! 🔗ow.ly/LZxv50VjUsK

Could Surgery Become Optional in Early Breast Cancer? Groundbreaking Trial Says Maybe! 🚨 OncoAlert 🎯 Objective: Evaluate if ☢️ alone can safely replace breast surgery in selected 👥 with early-stage invasive breast cancer 🏥 Methods: • Nonrandomized phase 2 trial (N=50) •

This is a fantastic journey. We have just concluded Europa trial enrollment!!!! Thanks to all patients ❤️❤️❤️❤️

📌 Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update ascopubs.org/doi/10.1200/JC… OncoAlert #OncoAlertAF ASCO

📌 Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study annalsofoncology.org/article/S0923-… OncoAlert #OncoAlertAF ESMO - Eur. Oncology 👉🏻 In the whole study

At #ESMOBreast25 mini oral session 1, Maria Carmen De Santis is reporting on a large and long-term analysis of post-mastectomy radiotherapy in HER2- positive #breastcancer patients of the BIG’s #ALTTO Trial! Serena Di Cosimo

It was a great pleasure present the long term results of PMRT in ALTTO trial. PMRT teduced locoregional recurrence in patients with positive lymphonodes and improved time to distant recurrence and overall survival in pN2 disease. These results confimed Oxford metanalysis.

SHARE trial - partial breast irradiation with twice-daily fractionation - no difference in cosmesis - few recurrence at 5-year median FU - APBI better any G2+ and worse breast G2+ toxicity #ASCO25 OncoAlert #OncoAlert #BreastCancer #radonc

SERENA-6 met primary endpoint (PFS): have the potential to become a new treatment paradigm in oncology to optimise first-line patient outcomes #ASCO25 Amazing presentation & subsequent discussion - need clinical utility demonstration before adoption OncoAlert #OncoAlert NEJM